Fashanu Oluwaseun E, Folsom Aaron R, Oyenuga Abayomi, Ballantyne Christie M, Lutsey Pamela L, Tang Weihong
Division of Epidemiology & Community Health, School of Public Health, University of MinnesotaMinneapolis, Minnesota, USA.
Department of Medicine, Baylor College of Medicine and Methodist DeBakey Heart and Vascular CenterHouston, Texas, USA.
Am J Cardiovasc Dis. 2017 Dec 20;7(6):114-121. eCollection 2017.
Galectin-3, a β-galactosidase binding lectin, known to be involved in inflammatory processes may be associated with abdominal aortic aneurysm (AAA) incidence. We examined the prospective association between plasma galectin-3 and incident AAA in 9,704 participants of the Atherosclerosis Risk in Communities (ARIC) study cohort. We followed participants from 1996-1998 through 2011 (124,260 person-years) for incident AAA (n=325) defined by ICD codes from hospital records and death certificates. At baseline, participants had a mean (SD) age of 62.8 (5.7) years; 20.9% were blacks and 56.5% females. The median (25-75 percentile) galectin-3 level was 14.2 (12.0-16.9) ng/mL. Galectin-3 was correlated positively with most cardiovascular risk factors and with several cardiac or inflammatory biomarkers (C-reactive protein, troponin-T, and NT-proBNP). Using Cox proportional hazards regression adjusted for demographic variables and measured AAA risk factors, the hazard ratios for AAA across galectin-3 quintiles were 1 (Referent), 1.54 (1.05-2.26), 1.58 (1.05-2.41), 1.76 (1.15-2.72), and 1.92 (1.22-3.01) (p for trend =0.01). Further adjustment for the cardiac and inflammatory biomarkers largely attenuated the association between galectin-3 and AAA [AAA hazard ratio for galectin-3 vs. : 1.29 (0.81-2.05); p-trend across quintiles =0.44]. In conclusion, higher concentrations of plasma galectin-3 were associated with greater incidence of AAA though not independent of other cardiac and inflammatory biomarkers. This reinforces that galectin-3, a systemic biomarker reflecting inflammation and probably increased systemic vascular resistance, is elevated early in the pathogenesis of AAA.
半乳糖凝集素-3是一种β-半乳糖苷结合凝集素，已知参与炎症过程，可能与腹主动脉瘤（AAA）的发病有关。我们在社区动脉粥样硬化风险（ARIC）研究队列的9704名参与者中，研究了血浆半乳糖凝集素-3与AAA发病之间的前瞻性关联。我们对参与者从1996年至1998年一直随访到2011年（共124260人年），以确定由医院记录和死亡证明中的ICD编码定义的AAA发病情况（n = 325）。基线时，参与者的平均（标准差）年龄为62.8（5.7）岁；20.9%为黑人，56.5%为女性。半乳糖凝集素-3水平的中位数（第25 - 75百分位数）为14.2（12.0 - 16.9）ng/mL。半乳糖凝集素-3与大多数心血管危险因素以及几种心脏或炎症生物标志物（C反应蛋白、肌钙蛋白-T和N末端脑钠肽前体）呈正相关。使用Cox比例风险回归模型，对人口统计学变量和测量的AAA危险因素进行校正后，AAA在半乳糖凝集素-3五分位数中的风险比分别为1（参照组）、1.54（1.05 - 2.26）、1.58（1.05 - 2.41）、1.76（1.15 - 2.72）和1.92（1.22 - 3.01）（趋势p值 = 0.01）。进一步对心脏和炎症生物标志物进行校正后，半乳糖凝集素-3与AAA之间的关联在很大程度上减弱了[半乳糖凝集素-3与AAA的风险比为：1.29（0.81 - 2.05）；五分位数间的p趋势 = 0.44]综上，血浆半乳糖凝集素-3浓度较高与AAA发病率较高相关，但并非独立于其他心脏和炎症生物标志物。这进一步证明，半乳糖凝集素-3作为一种反映炎症且可能增加全身血管阻力的系统性生物标志物，在AAA发病机制的早期就会升高。
